AroCell マネジメント

マネジメント基準チェック /04

AroCellの CEO はAnders Hultmanで、 Jan2021年に任命され、の在任期間は 3.83年です。は、会社の株式の0.49%を直接所有しており、その価値はSEK 560.00K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と2.7年です。

主要情報

Anders Hultman

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	3.8yrs
CEOの所有権	0.5%
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	2.7yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Anders Hultman (50 yo)

3.8yrs

在職期間

Mr. Anders Hultman, B.Sc., has been Chief Executive Officer at AroCell AB (publ) since January 11, 2021. He serves as Director at Polymer Factory Sweden AB since 2024. Mr. Hultman served as Chief Financial...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Anders Hultman	Chief Executive Officer	3.8yrs	データなし	0.49% SEK 560.0k
Lars Jakobsson	Acting Chief Financial Officer	less than a year	データなし	データなし
Jonas Söderholm	Global Medical Lead	no data	データなし	データなし
Gustav Sten	Chief Operating Officer	2.9yrs	データなし	0.036% SEK 42.0k
Kiran Jagarlamudi	Chief Scientific Officer	1.8yrs	データなし	0.0069% SEK 8.0k
Gunnar Wahlberg	Chief Sales Officer	less than a year	データなし	0.065% SEK 75.0k
Marie Torstensson	Chief Marketing Officer	less than a year	データなし	0.033% SEK 37.8k
Ellen Dittberner	Chief Finance Officer (Leave of Absence)	less than a year	データなし	データなし
Tina Yang	Chief Quality Officer	2.8yrs	データなし	0.0033% SEK 3.8k

1.3yrs

平均在職期間

経験豊富な経営陣: AROCの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Fredrik Lindgren	Director	less than a year	データなし	データなし
Clas Runnberg	Independent Director	1.8yrs	SEK 91.00k	0.11% SEK 125.4k
Staffan Eriksson	Member of Advisory Board	3.7yrs	SEK 60.00k	データなし
Max Pihlqvist	Chairman of the Board	2.8yrs	SEK 150.00k	12.49% SEK 14.4m
Eva Nordström	Independent Director	4.8yrs	SEK 150.00k	0.052% SEK 60.0k
Agneta Alm	Independent Director	2.5yrs	SEK 150.00k	0.0087% SEK 10.0k

2.7yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: AROCの取締役会は経験豊富ではない ( 2.7年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

AroCell マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

AroCell AB (publ), Annual General Meeting, May 22, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

High number of new directors

Recent updates

AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate Cancer

Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)

AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

AroCell AB (publ), Annual General Meeting, May 22, 2024

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Consensus revenue estimates fall by 12%

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

Price target decreased to kr2.30

High number of new and inexperienced directors

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

Price target decreased to kr2.00

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

Head of Operations recently bought kr81k worth of stock

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

New 90-day high: kr3.41

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

Head of Operations recently bought kr91k worth of stock

Head of Operations recently bought kr91k worth of stock

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

New 90-day low: kr2.43

Earnings released

New 90-day high - kr3.64

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04